Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing
Tim Mackey, Matthew Nali, Meng Zhen Larsen, Zhuoran Li, Jiawei Li, Joshua Yang

TL;DR
This study examines how easily Diamond Shruumz, a mushroom product linked to hospitalizations, remained available online after a recall, showing that many vendors continued to sell it.
Contribution
The study provides new insights into the challenges of enforcing recalls for emerging psychoactive substances in the online marketplace.
Findings
Before the recall, 4117 product listings were identified across social media, e-commerce sites, and search engines.
Post-recall, 67.16% of domains continued to market the product, and 33.33% successfully completed simulated purchases.
The study highlights the difficulty of enforcing recalls for such products in a rapidly evolving online market.
Abstract
Reports of hospitalization associated with Diamond Shruumz–branded mushroom-containing products in October 2024 led to a manufacturer’s recall that restricted the sale, distribution, and accessibility of this new and emerging psychoactive product. This study seeks to assess the continuing online availability of a mushroom-containing edible product in a diverse e-commerce landscape, specifically aiming to identify and characterize its online availability before and after recall initiation. A retrospective online market surveillance of Diamond Shruumz products using structured and automated search queries was employed to identify online product marketing and availability. Online surveillance included the monitoring of multiple social media platforms, cannabis e-commerce websites, and search engine queries between June 22 and June 27, 2024, immediately preceding the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Quality and Counterfeiting · Pharmaceutical industry and healthcare
